Literature DB >> 35220399

Caffeine treatment started before injury reduces hypoxic-ischemic white-matter damage in neonatal rats by regulating phenotypic microglia polarization.

Liu Yang1,2, Xuefei Yu1, Yajun Zhang3, Na Liu1, Xindong Xue1, Jianhua Fu4.   

Abstract

BACKGROUND: Reducing neuroinflammatory damage is an effective strategy for treating white-matter damage (WMD) in premature infants. Caffeine can ameliorate hypoxia-ischemia-induced brain WMD; however, its neuroprotective effect and mechanism against hypoxic-ischemic WMD remain unclear.
METHODS: We used 3-day-old Sprague-Dawley rats to establish a model of cerebral hypoxia-ischemia-induced brain WMD after unilateral common carotid artery ligation and hypoxia exposure (8% O2 + 92% N2) for 2.5 h. Mechanism experiments were conducted to detect M1/M2 polarization and activation of microglia and NLRP3 inflammasome.
RESULTS: Caffeine inhibited NLRP3 inflammasome activation, reduced microglial Iba-1 activation, inhibited microglia M1 polarization, and promoted microglia M2 polarization by downregulating CD86 and iNOS protein expression, inhibiting the transcription of the proinflammatory TNF-α and IL-1β, upregulating CD206 and Arg-1 expression, and promoting the transcription of the anti-inflammatory factors IL-10 and TGF-β. Importantly, we found that these caffeine-mediated effects could be reversed after inhibiting A2aR activity.
CONCLUSIONS: Caffeine improved long-term cognitive function in neonatal rats with hypoxic-ischemic WMD via A2aR-mediated inhibition of NLRP3 inflammasome activation, reduction of microglial activation, regulation of the phenotypic polarization of microglia and the release of inflammatory factors, and improvement of myelination development. IMPACT: The direct protective effect of caffeine on hypoxic-ischemic white-matter damage (WMD) and its mechanism remains unclear. This study elucidated this mechanism using neonatal rats as an animal model of hypoxia-ischemia-induced cerebral WMD. The findings demonstrated caffeine as a promising therapeutic tool against immature WMD to protect neonatal cognitive function. We found that caffeine pretreatment reduced WMD in immature brains via regulation of microglial activation and polarization by adenosine A2a receptor, thereby, providing a scientific basis for future clinical application of caffeine.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35220399     DOI: 10.1038/s41390-021-01924-6

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  65 in total

Review 1.  Encephalopathy of prematurity includes neuronal abnormalities.

Authors:  Joseph J Volpe
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

2.  Late preterm infants have worse 24-month neurodevelopmental outcomes than term infants.

Authors:  Melissa A Woythaler; Marie C McCormick; Vincent C Smith
Journal:  Pediatrics       Date:  2011-02-14       Impact factor: 7.124

Review 3.  Short- and Long-Term Outcomes of Moderate and Late Preterm Infants.

Authors:  Girija Natarajan; Seetha Shankaran
Journal:  Am J Perinatol       Date:  2016-01-20       Impact factor: 1.862

4.  Neurobehaviour at term-equivalent age and neurodevelopmental outcomes at 2 years in infants born moderate-to-late preterm.

Authors:  Alicia J Spittle; Jennifer M Walsh; Cody Potter; Emma Mcinnes; Joy E Olsen; Katherine J Lee; Peter J Anderson; Lex W Doyle; Jeanie L Y Cheong
Journal:  Dev Med Child Neurol       Date:  2016-10-24       Impact factor: 5.449

Review 5.  Adults born preterm: a review of general health and system-specific outcomes.

Authors:  Tonse N K Raju; A Sonia Buist; Carol J Blaisdell; Marva Moxey-Mims; Saroj Saigal
Journal:  Acta Paediatr       Date:  2017-05-17       Impact factor: 2.299

6.  Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia.

Authors:  Maj Hedtjärn; Carina Mallard; Henrik Hagberg
Journal:  J Cereb Blood Flow Metab       Date:  2004-12       Impact factor: 6.200

Review 7.  Inflammatory brain damage in preterm newborns--dry numbers, wet lab, and causal inferences.

Authors:  Olaf Dammann; Alan Leviton
Journal:  Early Hum Dev       Date:  2004-08       Impact factor: 2.079

Review 8.  Perinatal Brain Injury: Mechanisms, Prevention, and Outcomes.

Authors:  Christopher M Novak; Maide Ozen; Irina Burd
Journal:  Clin Perinatol       Date:  2018-03-21       Impact factor: 3.430

9.  A model of Periventricular Leukomalacia (PVL) in neonate mice with histopathological and neurodevelopmental outcomes mimicking human PVL in neonates.

Authors:  Nahla Zaghloul; Hardik Patel; Mohamed Nagy Ahmed
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

Review 10.  Brain damage of the preterm infant: new insights into the role of inflammation.

Authors:  Juliette Van Steenwinckel; Anne-Laure Schang; Stéphanie Sigaut; Vibol Chhor; Vincent Degos; Henrik Hagberg; Olivier Baud; Bobbi Fleiss; Pierre Gressens
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

View more
  4 in total

Review 1.  A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?

Authors:  Stefania Merighi; Manuela Nigro; Alessia Travagli; Silvia Pasquini; Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi; Stefania Gessi
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

2.  Caffeine Restores Neuronal Damage and Inflammatory Response in a Model of Intraventricular Hemorrhage of the Preterm Newborn.

Authors:  Pilar Alves-Martinez; Isabel Atienza-Navarro; Maria Vargas-Soria; Maria Jose Carranza-Naval; Carmen Infante-Garcia; Isabel Benavente-Fernandez; Angel Del Marco; Simon Lubian-Lopez; Monica Garcia-Alloza
Journal:  Front Cell Dev Biol       Date:  2022-08-12

Review 3.  Adenosine receptor signalling in Alzheimer's disease.

Authors:  Phuc N H Trinh; Jo-Anne Baltos; Shane D Hellyer; Lauren T May; Karen J Gregory
Journal:  Purinergic Signal       Date:  2022-07-23       Impact factor: 3.950

4.  Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model.

Authors:  Eduardo E Vargas-Pozada; Erika Ramos-Tovar; Juan D Rodriguez-Callejas; Irina Cardoso-Lezama; Silvia Galindo-Gómez; Daniel Talamás-Lara; Verónica Rocío Vásquez-Garzón; Jaime Arellanes-Robledo; Víctor Tsutsumi; Saúl Villa-Treviño; Pablo Muriel
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.